Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2007 Dec 7;13(4):423–443. doi: 10.1111/j.1527-3458.2007.00027.x

Cortagine: Behavioral and Autonomic Function of the Selective CRF Receptor Subtype 1 Agonist

Catherine Borna Farrokhi 1, Philip Tovote 3, Robert J Blanchard 1, D Caroline Blanchard 2, Yoav Litvin 1, Joachim Spiess 3
PMCID: PMC6494149  PMID: 18078427

ABSTRACT

Corticotropin‐releasing factor (CRF) is a neuropeptide and mediating component of neuroendocrine, autonomic, and behavioral processes associated with the stress response. The two receptor subtypes identified in the mammalian brain, CRF receptor subtype 1 (CRF1) and CRF2, are suggested to differentially modulate these processes. Manipulation of these receptors with selective CRF compounds and transgenic models has revealed, in most studies, a clear potentiation of the stress response through central activation of CRF1. However, pharmacological activation of CRF restricted to CRF1 has been limited by the availability of selective peptidic compounds. Recently, a highly selective CRF1 agonist, cortagine, has been developed. It was synthesized from chimeric intermediate sequences of ovine CRF, sauvagine, and human/rat CRF into a highly soluble peptide with strong affinity for CRF1 (IC50 < 5 nM) and a very low binding preference for CRF2 (IC50 > 500 nM). Affinity for the CRF binding protein (IC50 > 1,000nM) can be abolished by the addition of a glutamate residue on position 21 of the cortagine peptide sequence. Cortagine has recently been tested in a variety of preclinical models of behavior including the elevated‐plus‐maze (EPM), forced swim test (FST), homecage, and rat exposure test (RET). Preliminary characterization in the EPM and FST suggested that this compound elicits anxiogenic and antidepressant‐like effects, respectively. Additional testing in the homecage and RET, which targets various elements of behavior, directs to a more potent anxiogenic profile of cortagine. In this review, we discuss the behavioral findings and the tests used to measure these effects. Finally, we also discuss preliminary findings of autonomic activation obtained by central injection of cortagine that support CRF1 involvement in the modulation of heart rate and heart rate variability.

Keywords: Anxiety, Behavior, Cortagine, Corticotrophin, CRF1 agonist, CRH, Defense, Depression

Full Text

The Full Text of this article is available as a PDF (2.1 MB).

Conflict of Interest: The authors have no conflict of interest.

REFERENCES

  1. Antoni FA (1986) Hypothalamic control of adrenocorticotropin secretion: Advances since the discovery of 41‐residue corticotropin‐releasing factor. Endocr Rev 7:351‐378. [DOI] [PubMed] [Google Scholar]
  2. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin‐releasing factor in depression and anxiety disorders. J Endocrinol 160:1‐12. [DOI] [PubMed] [Google Scholar]
  3. Bagdy G, Graf M, Anheuer ZE, Modos EA, Kantor S (2001) Anxiety‐like effeccts induced by acute fluoxetine, sertraline or m‐CPP treatment are reversed by pretreatment with the 5‐HT2C receptor antagonist SB‐242084 but not the 5‐HT1A receptor antagonist WAY‐100635. Int J Neuropsychopharmacol 4:399‐408. [DOI] [PubMed] [Google Scholar]
  4. Bale TL, Vale WW (2003) Increased depression‐like behaviors in corticotropin‐releasing factor receptor‐2‐deficient mice: Sexually dichotomous responses. J Neurosci 23:5295‐5301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bale TL, Vale WW (2004) CRF and CRF receptors: Role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:525‐557. [DOI] [PubMed] [Google Scholar]
  6. Basso AM, Spina M, Rivier J, Vale W, Koob GF (1999) Corticotropin‐releasing factor antagonist attenuates the “anxiogenic‐like” effect in the defensive burying paradigm but not in the elevated plus‐maze following chronic cocaine in rats. Psychopharmacology (Berl) 145:21‐30. [DOI] [PubMed] [Google Scholar]
  7. Behbehani MM (1995) Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46:575‐605. [DOI] [PubMed] [Google Scholar]
  8. Blanchard DC, Blanchard RJ (1990) An ethoexperimental analysis of defense, fear, and anxiety Published in Anxiety, University of Otago Press, Dunedin . [Google Scholar]
  9. Blanchard DC, Blanchard RJ, Griebel G (2005) Defensive responses to predator threat in the rat and mouse Curr Protocols Neurosci 8.19.1–8.19.20. John Wiley & Sons. [DOI] [PubMed] [Google Scholar]
  10. Blanchard RJ, Griebel G, Hendrie JA, Blanchard DC (1997) Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci Biobehav Rev 21:783‐789. [DOI] [PubMed] [Google Scholar]
  11. Blanchard DC, Hynd AL, Minke KA, Minemoto T, Blanchard RJ (2001) Human defensive behaviors to threat scenarios show parallels to fear‐ and anxiety‐related defense patterns of non‐human mammals. Neurosci Biobehav Rev 25:761‐770. [DOI] [PubMed] [Google Scholar]
  12. Blanchard RJ, Shepherd JK, Rodgers RJ, Magee L, Blanchard DC (1993a) Attenuation of antipredator defensive behavior in rats following chronic treatment with imipramine. Psychopharmacology (Berl) 110:245‐253. [DOI] [PubMed] [Google Scholar]
  13. Blanchard RJ, Yudko EB, Rodgers RJ, Blanchard DC (1993b) Defense system psychopharmacology: An ethological approach to the pharmacology of fear and anxiety. Behav Brain Res 58:155‐165. [DOI] [PubMed] [Google Scholar]
  14. Bowers LK, Swisher CB, Behbehani MM (2003) Membrane and synaptic effects of corticotropin‐releasing factor on periaqueductal gray neurons of the rat. Brain Res 981:52‐57. [DOI] [PubMed] [Google Scholar]
  15. Bremner JD, Southwick SM, Darnell A, Charney DS (1996) Chronic PTSD in Vietnam combat veterans: Course of illness and substance abuse. Am J Psychiatry 153:369‐375. [DOI] [PubMed] [Google Scholar]
  16. Buwalda B, De Boer SF, Van Kalkeren AA, Koolhaas JM (1997) Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin‐releasing factor in the rat. Psychoneuroendocrinology 22:297‐309. [DOI] [PubMed] [Google Scholar]
  17. Canteras NS, Goto M (1999) Fos‐like immunoreactivity in the periaqueductal gray of rats exposed to a natural predator. Neuroreport 10:413‐418. [DOI] [PubMed] [Google Scholar]
  18. Carvalho‐Netto EF, Litvin Y, Nunes‐de‐Souza RL, Blanchard DC, Blanchard RJ (2007) Effects of intra‐PAG infusion of ovine CRF on defensive behaviors in Swiss‐Webster mice. Behav Brain Res 176:222‐229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cavalcante JC, Sita LV, Mascaro MB, Bittencourt JC, Elias CF (2006) Distribution of urocortin 3 neurons innervating the ventral premammillary nucleus in the rat brain. Brain Res 1089:116‐125. [DOI] [PubMed] [Google Scholar]
  20. Chalmers DT, Lovenberg TW, De Souza EB (1995). Localization of novel corticotropin‐releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15:6340‐6350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Chen CY, Doong ML, Rivier JE, Taché Y (2003) Intravenous urocortin II decreases blood pressure through CRF2 receptor in rats. Regul Pept 113:125‐130. [DOI] [PubMed] [Google Scholar]
  22. Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W, Gold LH (1999). Reduced anxiety‐like and cognitive performance in mice lacking the corticotropin‐releasing factor receptor 1. Brain Res 835:1‐9. [DOI] [PubMed] [Google Scholar]
  23. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin‐releasing hormone receptor‐2. Nat Genet 24:403‐409. [DOI] [PubMed] [Google Scholar]
  24. Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: Yet more partners discovered. Trends Pharmacol Sci 23:71‐77. [DOI] [PubMed] [Google Scholar]
  25. De Boer SF, Koolhaas JM (2003) Defensive burying in rodents: Ethology, neurobiology and psychopharmacology. Eur J Pharmacol 463:145‐161. [DOI] [PubMed] [Google Scholar]
  26. De Souza EB, Nemeroff CB (1990) Corticotropin‐releasing factor: Basic and clinical studies of a neuropeptide. CRC Press. [Google Scholar]
  27. Dielenberg RA, Hunt GE, McGregor IS (2001) “When a rat smells a cat”: The distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor. Neuroscience 104:1085‐1097. [DOI] [PubMed] [Google Scholar]
  28. Farrokhi C, Blanchard DC, Griebel G, Yang M, Gonzales C, Markham C, Blanchard RJ (2004) Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters. Pharmacol Biochem Behav 77:465‐469. [DOI] [PubMed] [Google Scholar]
  29. French JA, Fite JE, Jensen H, Oparowski K, Rukstalis MR, Fix H, Jones B, Maxwell H, Pacer M, Power ML, et al. (2007) Treatment with CRH‐1 antagonist antalarmin reduces behavioral and endocrine responses to social stressors in marmosets (Callithrix kuhlii). Am J Primatol (In press). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007) Corticotropin‐releasing factor 1 antagonists selectively reduce ethanol self‐administration in ethanol‐dependent rats. Biol Psychiatry 61:78‐86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Gammie SC, Stevenson SA (2006) Intermale aggression in corticotropin‐releasing factor receptor 1 deficient mice. Behav Brain Res 171:63‐69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Gehlert DR, Shekhar A, Morin SM, Hipskind PA, Zink C, Gackenheimer SL, Shaw J, Fitz SD, Sajdyk TJ (2005) Stress and central urocortin increase anxiety‐like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol 509:145‐153. [DOI] [PubMed] [Google Scholar]
  33. Gray TS (1990) The organization and possible function of amygdyloid corticotropin‐releasing factor pathways In: De Souza EB and Nemeroff CB, eds. Corticotropin releasing factor: Basic and clinical studies of a neuropeptide Florida : CRC Press, 53‐68. [Google Scholar]
  34. Gray JA, McNaughton N (2000) The neuropsychology of anxiety: An enquiry into the function of the septo‐hippocampal system, Vol. XVI Oxford , NY : Oxford University Press. [Google Scholar]
  35. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss‐Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berl) 120:57‐66. [DOI] [PubMed] [Google Scholar]
  36. Griebel G, Blanchard DC, Blanchard RJ (1996) Predator‐elicited flight responses in Swiss‐Webster mice: An experimental model of panic attacks. Prog Neuropsychopharmacol Biol Psychiatry 20:185‐205. [DOI] [PubMed] [Google Scholar]
  37. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK, Blanchard RJ (1995a) Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: Effects of acute and chronic treatment with alprazolam. Neuropharmacology 34:1625‐1633. [DOI] [PubMed] [Google Scholar]
  38. Griebel G, Blanchard DC, Jung A, Masuda CK, Blanchard RJ (1995b) 5‐HT1A agonists modulate mouse antipredator defensive behavior differently from the 5‐HT2A antagonist pirenperone. Pharmacol Biochem Behav 51:235‐244. [DOI] [PubMed] [Google Scholar]
  39. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrie P (2002) 4‐(2‐Chloro‐4‐methoxy‐5‐methylphenyl)‐N‐[(1S)‐2‐cyclopropyl‐1‐(3‐fluoro‐4‐methylphenyl)ethyl]5‐methyl‐N‐(2‐propynyl)‐1, 3‐thiazol‐2‐amine hydrochloride (SSR125543A), a potent and selective corticotrophin‐releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress‐related disorders. J Pharmacol Exp Ther 301:333‐345. [DOI] [PubMed] [Google Scholar]
  40. Gutman DA, Owens MJ, Skelton KH, Thrivikraman KV, Nemeroff CB (2003) The corticotropin‐releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J Pharmacol Exp Ther 304:874‐880. [DOI] [PubMed] [Google Scholar]
  41. Harro J, Tonissaar M, Eller M (2001) The effects of CRA 1000, a non‐peptide antagonist of corticotropin‐releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides 35:100‐109. [DOI] [PubMed] [Google Scholar]
  42. Heim C, Owens MJ, Plotsky PM, Nemeroff CB (1997) Persistent changes in corticotropin‐releasing factor systems due to early life stress: Relationship to the pathophysiology of major depression and post‐traumatic stress disorder. Psychopharmacol Bull 33:185‐192. [PubMed] [Google Scholar]
  43. Held K, Kunzel H, Ising M, Schmid DA, Zobel A, Murck H, Holsboer F, Steiger A (2004) Treatment with the CRH1‐receptor‐antagonist R121919 improves sleep‐EEG in patients with depression. J Psychiatr Res 38:129‐136. [DOI] [PubMed] [Google Scholar]
  44. Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005) Limbic system mechanisms of stress regulation: Hypothalamo‐pituitary‐adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201‐1213. [DOI] [PubMed] [Google Scholar]
  45. Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE, Guzzi MF, Parker EM, Varty GB (2007) Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP‐154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 86:431‐440. [DOI] [PubMed] [Google Scholar]
  46. Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin‐related peptide are selective ligands for the type 2 corticotropin‐releasing hormone receptor. Nat Med 7:605‐611. [DOI] [PubMed] [Google Scholar]
  47. Jones DN, Kortekaas R, Slade PD, Middlemiss DN, Hagan JJ (1998) The behavioural effects of corticotropin‐releasing factor‐related peptides in rats. Psychopharmacology (Berl) 138:124‐132. [DOI] [PubMed] [Google Scholar]
  48. Kalin NH, Shelton SE, Kraemer GW, McKinney WT (1983) Corticotropin‐releasing factor administered intraventricularly to rhesus monkeys. Peptides 4:217‐220. [DOI] [PubMed] [Google Scholar]
  49. Kostich WA, Grzanna R, Lu NZ, Largent BL (2004) Immunohistochemical visualization of corticotropin‐releasing factor type 1 (CRF1) receptors in monkey brain. J Comp Neurol 478:111‐125. [DOI] [PubMed] [Google Scholar]
  50. Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH‐1‐receptor antagonist R121919: Endocrine changes and side effects. J Psychiatr Res 37:525‐533. [DOI] [PubMed] [Google Scholar]
  51. Lancel M, Muller‐Preuss P, Wigger A, Landgraf R, Holsboer F (2002) The CRH1 receptor antagonist R121919 attenuates stress‐elicited sleep disturbances in rats, particularly in those with high innate anxiety. J Psychiatr Res 36:197‐208. [DOI] [PubMed] [Google Scholar]
  52. Lelas S, Wong H, Li YW, Heman KL, Ward KA, Zeller KL, Sieracki KK, Polino JL, Godonis HE, Ren SX, et al. (2004) Anxiolytic‐like effects of the corticotropin‐releasing factor1 (CRF1) antagonist DMP904 [4‐(3‐pentylamino)‐2,7‐dimethyl‐8‐(2‐methyl‐4‐methoxyphenyl)‐pyrazolo‐[1,5‐a]‐pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats. J Pharmacol Exp Ther 309:293‐302. [DOI] [PubMed] [Google Scholar]
  53. Li C, Vaughan J, Sawchenko PE, Vale WW (2002) Urocortin III‐immunoreactive projections in rat brain: Partial overlap with sites of type 2 corticotropin‐releasing factor receptor expression. J Neurosci 22:991‐1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Li YW, Fitzgerald L, Wong H, Lelas S, Zhang G, Lindner MD, Wallace T, McElroy J, Lodge NJ, Gilligan P, et al. (2005) The pharmacology of DMP696 and DMP904, non‐peptidergic CRF1 receptor antagonists. CNS Drug Rev 11:21‐52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Lim MM, Tsivkovskaia NO, Bai Y, Young LJ, Ryabinin AE (2006) Distribution of corticotropin‐releasing factor and urocortin 1 in the vole brain. Brain Behav Evol 68:229‐240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Litvin Y, Pentkowski N, Blanchard DC, Blanchard RJ (2007) CRF type 1 receptors in the dorsal periaqueductal gray modulate anxiety‐induced defensive behaviors. Horm Behav 52:244‐251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Lovenberg TW, Chalmers DT, Liu C, De Souza EB (1995) CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 136:4139‐4142. [DOI] [PubMed] [Google Scholar]
  58. Lowry CA, Moore FL (2006) Regulation of behavioral responses by corticotropin‐releasing factor. Gen Comp Endocrinol 146:19‐27. [DOI] [PubMed] [Google Scholar]
  59. Maier SF, Seligman SEP (1976) Learned helplessness: Theory and evidence. J Exp Psychol Gen 105:3‐46. [Google Scholar]
  60. Menzaghi F, Howard RL, Heinrichs SC, Vale W, Rivier J, Koob GF (1994) Characterization of a novel and potent corticotropin‐releasing factor antagonist in rats. J Pharmacol Exp Ther 269:564‐572. [PubMed] [Google Scholar]
  61. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W (1984) Elevated concentrations of CSF corticotropin‐releasing factor‐like immunoreactivity in depressed patients. Science 226:1342‐1344. [DOI] [PubMed] [Google Scholar]
  62. Nerozzi D, Bersani G, Melia E, Magnani A, Antonozzi I, Frajese G (1988) Corticotropin‐releasing factor and adrenal function in major depression. J Endocrinol Invest 11:697‐701. [DOI] [PubMed] [Google Scholar]
  63. Overstreet DH, Griebel G (2004) Antidepressant‐like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 497:49‐53. [DOI] [PubMed] [Google Scholar]
  64. Overton J, Fisher L (1991) Differentiated hemodynamic responses to central versus peripheral administration of corticotropin‐releasing factor in conscious rats. J Autonom Nerv Syst 35:43‐52. [DOI] [PubMed] [Google Scholar]
  65. Parkes DG, Weisinger RS, May CN (2001) Cardiovascular actions of CRH and urocortin: An update. Peptides 22:821‐827. [DOI] [PubMed] [Google Scholar]
  66. Pelleymounter MA, Joppa M, Ling N, Foster AC (2002) Pharmacological evidence supporting a role for central corticotropin‐releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302:145‐152. [DOI] [PubMed] [Google Scholar]
  67. Petit‐Demouliere B, Chenu F, Bourin M (2005) Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology (Berl) 177:245‐255. [DOI] [PubMed] [Google Scholar]
  68. Porsolt RD (1979) Animal model of depression. Biomedicine 30:139‐140. [PubMed] [Google Scholar]
  69. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: A new animal model sensitive to antidepressant treatments. Nature 266:730‐732. [DOI] [PubMed] [Google Scholar]
  70. Richter R, Mulvany M (1995) Comparison of hCRF and oCRF effects on cardiovascular responses after central, peripheral, and in vitro application. Peptides 16:843‐849. [DOI] [PubMed] [Google Scholar]
  71. Rivier J, Gulyas J, Kunitake K, DiGruccio M, Cantle JP, Perrin MH, Donaldson C, Vaughan J, Million M, Gourcerol G, et al. (2007) Stressin1‐A, a potent corticotropin releasing factor receptor 1 (CRF1)‐selective peptide agonist. J Med Chem 50:1668‐1674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sanchez MM, Young LJ, Plotsky PM, Insel TR (1999) Autoradiographic and in situ hybridization localization of corticotropin‐releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408:365‐377. [PubMed] [Google Scholar]
  73. Sautter FJ, Bissette G, Wiley J, Manguno‐Mire G, Schoenbachler B, Myers L, Johnson JE, Cerbone A, Malaspina D (2003) Corticotropin‐releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 54:1382‐1388. [DOI] [PubMed] [Google Scholar]
  74. Sheehan TP, Chambers RA, Russell DS (2004) Regulation of affect by the lateral septum: Implications for neuropsychiatry. Brain Res Brain Res Rev 46:71‐117. [DOI] [PubMed] [Google Scholar]
  75. Skelton KH, Gutman DA, Thrivikraman KV, Nemeroff CB, Owens MJ (2007) The CRF(1) receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. Psychopharmacology (Berl) (In press). [DOI] [PubMed] [Google Scholar]
  76. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, et al. (1998) Corticotropin releasing factor receptor 1‐deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093‐1102. [DOI] [PubMed] [Google Scholar]
  77. Spiess J, Rivier J, Rivier C, Vale WW (1981) Primary structure of corticotropin‐releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A 78:6517‐6521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD (1987) The automated tail suspension test: A computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11:659‐671. [DOI] [PubMed] [Google Scholar]
  79. Stiedl O, Meyer M, Jahn O, Ogren SO, Spiess J (2005) Corticotropin‐releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear. J Pharmacol Exp Ther 312:905‐916. [DOI] [PubMed] [Google Scholar]
  80. Stiedl O, Meyer M, Kishimoto T, Rosenfeld MG, Spiess J (2003) Stress‐mediated heart rate dynamics after deletion of the gene encoding corticotropin‐releasing factor receptor 2. Eur J Neurosci 17:2231‐2235. [DOI] [PubMed] [Google Scholar]
  81. Takahashi LK (2001) Role of CRF(1) and CRF(2) receptors in fear and anxiety. Neurosci Biobehav Rev 25:627‐636. [DOI] [PubMed] [Google Scholar]
  82. Tezval H, Jahn O, Todorovic C, Sasse A, Eckart K, Spiess J (2004) Cortagine, a specific agonist of corticotropin‐releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc Natl Acad Sci U S A 101:9468‐9473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin‐releasing hormone receptor 1. Nat Genet 19:162‐166. [DOI] [PubMed] [Google Scholar]
  84. Todorovic C, Jahn O, Tezval H, Hippel C, Spiess J (2005) The role of CRF receptors in anxiety and depression: Implications of the novel CRF1 agonist cortagine. Neurosci Biobehav Rev 29:1323‐1333. [DOI] [PubMed] [Google Scholar]
  85. Valdez GR (2006) Development of CRF1 receptor antagonists as antidepressants and anxiolytics: Progress to date. CNS Drugs 20:887‐896. [DOI] [PubMed] [Google Scholar]
  86. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP (2002) Human urocortin II: Mild locomotor suppressive and delayed anxiolytic‐like effects of a novel corticotropin‐releasing factor related peptide. Brain Res 943:142‐150. [DOI] [PubMed] [Google Scholar]
  87. Vale WW, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41‐residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta‐endorphin. Science 213:1394‐1397. [DOI] [PubMed] [Google Scholar]
  88. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C, Prins GS, Perrin M, Vale W, Sawchenko PE (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428:191‐212. [DOI] [PubMed] [Google Scholar]
  89. Whitnall MH (1993) Regulation of the hypothalamic corticotropin‐releasing hormone neurosecretory system. Prog Neurobiol 40:573‐629. [DOI] [PubMed] [Google Scholar]
  90. Widerlov E, Bissette G, Nemeroff CB (1988) Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. J Affect Disord 14:99‐107. [DOI] [PubMed] [Google Scholar]
  91. Yang M, Augustsson H, Markham CM, Hubbard DT, Webster D, Wall PM, Blanchard RJ, Blanchard DC (2004) The rat exposure test: A model mouse defensive behaviors. Physiol Behav 81:465‐473. [DOI] [PubMed] [Google Scholar]
  92. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000) Effects of the high‐affinity corticotropin‐releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated. J Psychiatr Res 34:171‐181. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES